OncoMatch/Sarcoma/CDK4 amplification (liposarcoma)
SarcomaCDK4 amplification (liposarcoma) Clinical Trials
CDK4 amplification — co-occurring with MDM2 amplification on 12q13-15 — defines well-differentiated and dedifferentiated liposarcoma, among the most common sarcoma subtypes. CDK4 inhibitors (palbociclib, abemaciclib, ribociclib) have been studied in CDK4-amplified sarcoma with modest activity. Trials investigate CDK4/6 inhibitor combinations with MDM2 antagonists (milademetan, siremadlin), novel CDK4-selective agents, and immunotherapy for dedifferentiated liposarcoma.
Top recruiting CDK4 amplification (liposarcoma) Sarcoma trials
Ranked by phase and US site count. See all 2 trials matched to your profile →
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Medical College of Wisconsin
Browse other molecular targets with active Sarcoma trials.